Three different drugs developed in Finland have received a marketing authorization during the past year, and a positive decision is expected on the application of a fourth marketing authorization.
The FDA has granted a marketing authorization for two drugs developed in Turku, Finland--the IUD Skyla, developed, by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. With the marketing authorization of Selincro, a Biotie drug intended for the treatment of alcohol addiction, granted by the EMA, that brings the total number of drugs developed in Turku and granted marketing authorizations to three, with a fourth expected to follow.
There are only about 30 new drugs that receive the marketing authorization in Europe per year, a number that makes the turnout from Turku even more significant.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.